ClinicalTrials.Veeva

Menu
N

Newport Huntington Medical Group | Huntington Beach, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Upadacitinib
ABT-494
Ixekizumab
Guselkumab
Tirzepatide
Peresolimab
Mirikizumab
LY3871801
Adalimumab
Risankizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 18 total trials

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

Active, not recruiting
Crohn's Disease
Drug: Mirikizumab

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by...

Enrolling
Arthritis, Psoriatic
Drug: Placebo
Drug: Guselkumab

The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis...

Enrolling
Rheumatoid Arthritis
Drug: LY3541860

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large...

Enrolling
Ulcerative Colitis
Drug: Lutikizumab Matching Placebo
Drug: Adalimumab Matching Placebo

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the...

Enrolling
Crohn's Disease
Drug: Placebo for risankizumab
Drug: Risankizumab SC

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: Placebo
Drug: Upadacitinib (ABT-494)

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participan...

Enrolling
Overweight or Obesity
Psoriatic Arthritis
Drug: Tirzepatide

The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid...

Enrolling
Rheumatoid Arthritis
Drug: LY3871801
Drug: Placebo

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate re...

Active, not recruiting
Arthritis, Psoriatic
Drug: Placebo
Drug: Guselkumab

The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at leas...

Active, not recruiting
Obesity
Psoriatic Arthritis
Drug: Tirzepatide
Drug: Ixekizumab
Locations recently updated

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how s...

Enrolling
Systemic Lupus Erythematosus
Drug: Upadacitinib
Drug: Placebo

Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how...

Enrolling
Rheumatoid Arthritis
Drug: Adalimumab
Drug: Upadacitinib

Trial sponsors

AbbVie logo
Lilly logo
Janssen (J&J Innovative Medicine) logo
I

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems